Expression of an antisense transforming growth factor-β1 transgene reduces tumorigenicity of EMT6 mammary tumor cells

Cancer Gene Therapy

Volumn 4, Issue 1, 1997, Pages 42-50

  Park, Julie A ^a   Wang, Ena ^a   Kurt, Robert A ^a   Schluter, Samuel F ^a   Hersh, Evan M ^b   Akporiaye, Emmanuel T ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antisense TGF ; Antitumor immunity; EMT6 mammary carcinoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; CELL CYCLE; CELL DIVISION; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MOUSE; PATHOLOGY; PHYSIOLOGY; TRANSGENE;

ANIMALS; CELL CYCLE; CELL DIVISION; FEMALE; GENE EXPRESSION; IMMUNE TOLERANCE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES, ANTISENSE; TRANSFORMING GROWTH FACTOR BETA; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 0030639334     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Massague J. The transforming growth factor-β family. Ann Rev Cell Biol. 1990;6:597-641.
2. Miyazono K, Dijke PT, Ichijo H, Heldin C-H. Receptors for transforming growth factor-β. Adv Immunol. 1994;55: 181-220.
3. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986;136:1037-1050.
4. Uhm J-R, Kettering JD, Gridley DS. Modulation of transforming growth factor-β1 effects by cytokines. Immunol Invest. 1993;22:375-388.
5. Gray JD, Hirokawa M, Horwitz DA. The role of transforming growth factor β in the generation of suppression: an interaction between CD8+ and NK cells. J Exp Med. 1994;180:1937-1942.
6. Espevik T, Waage A, Faxvaage A, Shalaby R. Regulation of interleukin-2 and interleukin-6 production from T cells: involvement of interleukin-1 β and transforming growth factor-β. Cell Immunol. 1990;126:47-56.
7. Kuppner MC, Hamou M-F, Sawamura Y, Bodmer S, De Tribolet N. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2. J Neurosurg. 1989;71:211-217.
8. Mule JJ, Schwartz SL, Roberts AB, Sporn MB, Rosenberg SA. Transforming growth factor beta inhibits the in vitro generation of lymphokine activated killer cells and cytotoxic T cells. Cancer Immunol Immunother. 1988;26:95-100.
9. Ranges GE, Figari IS, Terje E, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor âand reversal by recombinant tumor necrosis factor α. J Exp Med. 1987;166:991-998.
10. Repique CJ, Kettering JD, Gridley DS. Immunosuppression derived from human B-lymphoblastoid and melanoma cell lines. Cancer Invest. 1992;10:201-208.
11. Dalal BI, Keown PA, Greenberg A. Immunocytochemical localization of secreted transforming growth factor-β1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol. 1993;143:381-389.
12. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res. 1992;52:6949-6952.
13. McCune BK, Mullin BR, Flanders KC, Jaffurs WJ, Mullen LT, Sporn MB. Localization of transforming growth factor β isotypes in lesions of the human breast. Hum Pathol. 1992;23:13-20.
14. Wallick SC, Figari IS, Morris RE, Levinson AD, Palladino MA. Immunoregulatory role of transforming growth factor β (TGF-β) in development of killer cells. Comparison of active and latent TGF-β. J Exp Med. 1990;172:1777-1784.
15. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. A highly immunogenic tumor transfected with a murine transforming growth factor β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA. 1990;87:1486-1490.
16. Chang H-L, Gillet N, Figari I, Lopez AR, Palladino MA, Dernyck R. Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res. 1993;53:4391-4398.
17. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K. Excessive production of transforming growth factor ßl can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta. 1992;1137:189-196.
18. Steiner MS, Barrack ER. Transforming growth factor-β1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol. 1992;6:15-25.
19. Rockwell SC, Kallman RF, Fajardo LF. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst. 1972; 49:735-747.
20. Chou Q, Russell M, Birch DE, Raymond J, Bloch W. Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplification. Nucleic Acids Res. 1992;20:1717-1723.
21. Derynck R, Jarrett JA, Chen EY, Goeddel DV. The murine transforming growth factor-β precursor. J Biol Chem. 1986;261:4377-4379.
22. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7:980-990.
23. Lucas C, Fendly BM, Mukku VR, Wong WL, Palladino MA. Generation of antibodies and assays for transforming growth factor β. Methods Enzymol. 1991;198:303-316.
24. Carlsson G, Gullberg B, Hafstrom L. Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol. 1983;105:20-23.
25. McAdam AJ, Felcher A, Woods ML, Pulaski BA, Hutter EK, Frelinger JG, Lord EM. Transfection of transforming growth factor-β producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immnunother. 1994;15:155-164.
26. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors. 1994;11:29-44.
27. Wu S, Theodorescu D, Kerbel RS, Wilson JKV, Mulder KM, Humphrey LE, Brattain G. TGF-β1 is an autocrinenegative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an anti-sense expression vector. J Cell Biol 1992;116:187-196.
28. Rodeck U, Bossier A, Graeven U, Fox FE, Nowll PC, Knabbe C, Kari C. Transforming frowth factor β production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 1994;54:575-581.
29. Suardet L, Gaide A-C, Calmes J-M, Sordat B, Givel J-C, Eliason JF, Odartchenko N. Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors β1 and β2. Cancer Res. 1992; 52:3705-3712.
30. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol, RE. Eradication of established intracranial rat gliomas by transforming growth factor âantisense gene therapy. Proc Natl Acad Sci USA. 1996;93:2909-2914.